BEAM Stock Chart & Stats
$535.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$309.00 - $655.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.00
Market Cap
$45.15B
Enterprise Value$1.50K
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$250.82M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Aug 11, 2026EPS Estimate
-19.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding102,879,210
10 Day Avg. Volume1
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$926.38Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthModest leverage and a sizable equity base provide durable financial flexibility for a pre-revenue biotech. A stronger balance sheet reduces near-term refinancing risk, supports R&D spending and partner collaborations, and extends runway while programs advance through clinical stages.
Revenue Growth TrendSustained top-line growth demonstrates strengthening commercial or partner-derived income and validates the platform's market relevance. Continued revenue gains improve optionality to fund development, increase partner interest, and can progressively offset R&D fixed costs over the medium term.
Governance ContinuityClear shareholder support for the board and leadership reduces governance uncertainty during lengthy development timelines. Continuity aids execution of long-term strategy, preserves strategic partnerships, and maintains consistent oversight of clinical and regulatory programs.
Bears Say
Heavy Cash BurnMaterial negative operating and free cash flow indicate persistent financing needs. Over a multi-month horizon this increases reliance on equity or partner funding, risks dilution or covenant constraints, and can force program prioritization that delays or narrows pipeline development.
Sustained UnprofitabilityDeep negative margins reflect absence of commercial product revenue and high development costs. Without a clear path to margin improvement, profitability remains distant, limiting internal cash generation and magnifying dependence on external capital and milestone-driven revenues.
Revenue Dependence On CollaborationsA business model reliant on upfronts, R&D reimbursements, milestones and future royalties creates lumpy, partner-contingent cash flows. This structural dependence reduces revenue predictability and ties material funding to partner development success and external regulatory outcomes.
BEAM FAQ
What was Beam Therapeutics, Inc.’s price range in the past 12 months?
Beam Therapeutics, Inc. lowest stock price was $309.00 and its highest was $655.00 in the past 12 months.
What is Beam Therapeutics, Inc.’s market cap?
Beam Therapeutics, Inc.’s market cap is $45.15B.
When is Beam Therapeutics, Inc.’s upcoming earnings report date?
Beam Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 16 days.
How were Beam Therapeutics, Inc.’s earnings last quarter?
Beam Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$15.933 earnings per share for the quarter, beating the consensus estimate of -$17.999 by $2.066.
Is Beam Therapeutics, Inc. overvalued?
According to Wall Street analysts Beam Therapeutics, Inc.’s price is currently Undervalued.
Does Beam Therapeutics, Inc. pay dividends?
Beam Therapeutics, Inc. does not currently pay dividends.
What is Beam Therapeutics, Inc.’s EPS estimate?
Beam Therapeutics, Inc.’s EPS estimate is -19.36.
How many shares outstanding does Beam Therapeutics, Inc. have?
Beam Therapeutics, Inc. has 102,879,210 shares outstanding.
What happened to Beam Therapeutics, Inc.’s price movement after its last earnings report?
Beam Therapeutics, Inc. reported an EPS of -$15.933 in its last earnings report, beating expectations of -$17.999. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Beam Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MX:BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$926.38 (― Downside)
$926.38 (― Downside)
Blogger Sentiment
Bullish
MX:BEAM Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Beam Therapeutics, Inc.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Stock 12 Month Forecast
Average Price Target
$926.38